- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe rheumatoid arthritis
- Meeting Date: July 2013
- Public Summary Document (PSD) July 2013 PBAC Meeting - PDF
Tocilizumab – July 2013
Tocilizumab, solution for IV infusion, 80 mg in 4 mL, 200 mg in 10 mL and 400 mg in 20 mL, Actemra®
Last updated
8 November 2023